Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Condition(s) studied

Investigational drug(s) / intervention(s)

Dexamethasone: Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.

Targeted blood pressure management: Blood pressure is maintained within ±10% from baseline.

Placebo: Placebo (2 ml normal saline) is administered before anesthesia induction.

Routine blood presure management: Blood pressure is maintained according to routine practice.

Study summary

Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.

Eligibility

Primary outcome measure(s)

• Overall survival after surgery — Up to 5 years after surgery
  Overall survival after surgery
• Incidence of organ injury and complications within 5 days after surgery (sub-study). — Up to 5 days after surgery.
  Organ injury includes delirium, acute kidney injury and myocardial injury. Postoperative complications are generally defined as newly occurred medical conditions that are harmful to patients' recovery and required therapeutic intervention, i.e., grade II or above on the Clavien-Dindo classification.

Trial sites (1)

More Peking University First Hospital trials in China

Other trials for the same condition